Our results have shown that there was no significant difference in the efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC and a PD-L1 TPS ≥ 50% aged 70 and older when compared to their younger counterparts. The gene discussed is CD274; the disease is non-small cell lung carcinoma.